XML 31 R13.htm IDEA: XBRL DOCUMENT v3.19.2
Leases
6 Months Ended
Jun. 30, 2019
Leases [Abstract]  
Leases
Leases

The Company leases most of its retail stores and mail order facilities and certain distribution centers and corporate offices under operating or finance leases, typically with initial terms of 15 to 25 years. The Company also leases certain equipment and other assets under operating or finance leases, typically with initial terms of 3 to 10 years.

The Company maintains certain lease agreements for which the noncancelable contractual term of the pharmacy lease arrangement exceeds the remaining estimated economic life of the buildings being leased. For these pharmacy lease agreements, the Company concluded that for accounting purposes the lease term was the remaining economic life of the buildings. Consequently, most of these individual pharmacy leases are finance leases.

The following table is a summary of the Company’s components of net lease cost for the three and six months ended June 30, 2019:
In millions
Three Months Ended
June 30, 2019
 
Six Months Ended
June 30, 2019
Operating lease cost
$
681

 
$
1,363

Finance lease cost:
 
 
 
Amortization of right-of-use assets
9

 
18

Interest on lease liabilities
11

 
21

Total finance lease costs
20

 
39

Short-term lease costs
6

 
12

Variable lease costs
144

 
286

Less: sublease income
10

 
22

Net lease cost
$
841

 
$
1,678


Supplemental cash flow information related to leases for the six months ended June 30, 2019 is as follows:
In millions
 
Cash paid for amounts included in the measurement of lease liabilities:
 
Operating cash flows paid for operating leases
$
1,348

Operating cash flows paid for interest portion of finance leases
21

Financing cash flows paid for principal portion of finance leases
13

Right-of-use assets obtained in exchange for lease obligations:
 
Operating leases
868

Finance leases
43



Supplemental balance sheet information related to leases as of June 30, 2019 is as follows:
In millions, except lease term and discount rate
 
Operating leases:
 
Operating lease right-of-use assets
$
20,865

 
 
Current portion of operating lease liabilities
$
1,793

Long-term operating lease liabilities
18,849

Total operating lease liabilities
$
20,642

 
 
Finance leases: (1)
 
Property and equipment, net
$
531

 
 
Current portion of long-term debt
$
26

Long-term debt
559

Total finance lease liabilities
$
585

 
 
Weighted average remaining lease term
 
Operating leases
14.0

Finance leases
20.3

 
 
Weighted average discount rate
 
Operating leases
4.7
%
Finance leases
7.4
%
_____________________________________________ 
(1)
Finance lease right-of-use assets are included within property and equipment, net and the respective finance lease liabilities are included in the current portion of long-term debt and long-term debt lines on the unaudited condensed consolidated balance sheets.

The following table summarizes the maturity of lease liabilities under finance and operating leases as of June 30, 2019:
 
Finance
 
Operating
 
 
In millions
Leases
 
Leases (1)
 
Total
2019 (remaining six months)
$
34

 
$
1,356

 
$
1,390

2020
68

 
2,645

 
2,713

2021
65

 
2,516

 
2,581

2022
61

 
2,356

 
2,417

2023
59

 
2,244

 
2,303

Thereafter
825

 
16,857

 
17,682

Total lease payments (2)
1,112

 
27,974

 
29,086

Less: imputed interest
(527
)
 
(7,332
)
 
(7,859
)
Total lease liabilities
$
585

 
$
20,642

 
$
21,227


_____________________________________________ 
(1)
Future operating lease payments have not been reduced by minimum sublease rentals of $327 million due in the future under noncancelable subleases.
(2)
The Company leases pharmacy and clinic space from Target Corporation. Amounts related to such finance and operating leases are reflected above. Pharmacy lease amounts due in excess of the remaining estimated economic life of the buildings of approximately $2.2 billion are not reflected herein since the estimated economic life of the buildings is shorter than the contractual term of the pharmacy lease arrangement.

The Company finances a portion of its store development program through sale-leaseback transactions. The properties are generally sold at net book value, which generally approximates fair value, and the resulting leases generally qualify and are accounted for as operating leases. The operating leases that resulted from these transactions are included in the table above. The Company does not have any retained or contingent interests in the stores and does not provide any guarantees, other than a guarantee of lease payments, in connection with the sale-leaseback transactions. Sale-leaseback transactions resulted in an
immaterial gain and proceeds of $5 million in the six months ended June 30, 2019. There were no sale-leaseback transactions in the three months ended June 30, 2019 or the three and six months ended June 30, 2018.

Store Rationalization Charge
During the six months ended June 30, 2019, the Company performed a review of its retail stores and determined it would close 46 underperforming retail pharmacy stores during the second quarter of 2019. As a result, management determined that there were indicators of impairment with respect to the impacted stores, including the operating lease right-of-use assets. Accordingly, an interim long lived asset impairment test was performed. The results of the impairment test indicated that the fair value of each store asset group was lower than the carrying value. The fair value was determined using a discounted cash flow method based on estimated sublease income. In the six months ended June 30, 2019, the Company recorded a store rationalization charge of $135 million, primarily related to these operating lease right-of-use asset impairment charges, which was recorded within operating expenses in the Retail/LTC Segment.
Leases
Leases

The Company leases most of its retail stores and mail order facilities and certain distribution centers and corporate offices under operating or finance leases, typically with initial terms of 15 to 25 years. The Company also leases certain equipment and other assets under operating or finance leases, typically with initial terms of 3 to 10 years.

The Company maintains certain lease agreements for which the noncancelable contractual term of the pharmacy lease arrangement exceeds the remaining estimated economic life of the buildings being leased. For these pharmacy lease agreements, the Company concluded that for accounting purposes the lease term was the remaining economic life of the buildings. Consequently, most of these individual pharmacy leases are finance leases.

The following table is a summary of the Company’s components of net lease cost for the three and six months ended June 30, 2019:
In millions
Three Months Ended
June 30, 2019
 
Six Months Ended
June 30, 2019
Operating lease cost
$
681

 
$
1,363

Finance lease cost:
 
 
 
Amortization of right-of-use assets
9

 
18

Interest on lease liabilities
11

 
21

Total finance lease costs
20

 
39

Short-term lease costs
6

 
12

Variable lease costs
144

 
286

Less: sublease income
10

 
22

Net lease cost
$
841

 
$
1,678


Supplemental cash flow information related to leases for the six months ended June 30, 2019 is as follows:
In millions
 
Cash paid for amounts included in the measurement of lease liabilities:
 
Operating cash flows paid for operating leases
$
1,348

Operating cash flows paid for interest portion of finance leases
21

Financing cash flows paid for principal portion of finance leases
13

Right-of-use assets obtained in exchange for lease obligations:
 
Operating leases
868

Finance leases
43



Supplemental balance sheet information related to leases as of June 30, 2019 is as follows:
In millions, except lease term and discount rate
 
Operating leases:
 
Operating lease right-of-use assets
$
20,865

 
 
Current portion of operating lease liabilities
$
1,793

Long-term operating lease liabilities
18,849

Total operating lease liabilities
$
20,642

 
 
Finance leases: (1)
 
Property and equipment, net
$
531

 
 
Current portion of long-term debt
$
26

Long-term debt
559

Total finance lease liabilities
$
585

 
 
Weighted average remaining lease term
 
Operating leases
14.0

Finance leases
20.3

 
 
Weighted average discount rate
 
Operating leases
4.7
%
Finance leases
7.4
%
_____________________________________________ 
(1)
Finance lease right-of-use assets are included within property and equipment, net and the respective finance lease liabilities are included in the current portion of long-term debt and long-term debt lines on the unaudited condensed consolidated balance sheets.

The following table summarizes the maturity of lease liabilities under finance and operating leases as of June 30, 2019:
 
Finance
 
Operating
 
 
In millions
Leases
 
Leases (1)
 
Total
2019 (remaining six months)
$
34

 
$
1,356

 
$
1,390

2020
68

 
2,645

 
2,713

2021
65

 
2,516

 
2,581

2022
61

 
2,356

 
2,417

2023
59

 
2,244

 
2,303

Thereafter
825

 
16,857

 
17,682

Total lease payments (2)
1,112

 
27,974

 
29,086

Less: imputed interest
(527
)
 
(7,332
)
 
(7,859
)
Total lease liabilities
$
585

 
$
20,642

 
$
21,227


_____________________________________________ 
(1)
Future operating lease payments have not been reduced by minimum sublease rentals of $327 million due in the future under noncancelable subleases.
(2)
The Company leases pharmacy and clinic space from Target Corporation. Amounts related to such finance and operating leases are reflected above. Pharmacy lease amounts due in excess of the remaining estimated economic life of the buildings of approximately $2.2 billion are not reflected herein since the estimated economic life of the buildings is shorter than the contractual term of the pharmacy lease arrangement.

The Company finances a portion of its store development program through sale-leaseback transactions. The properties are generally sold at net book value, which generally approximates fair value, and the resulting leases generally qualify and are accounted for as operating leases. The operating leases that resulted from these transactions are included in the table above. The Company does not have any retained or contingent interests in the stores and does not provide any guarantees, other than a guarantee of lease payments, in connection with the sale-leaseback transactions. Sale-leaseback transactions resulted in an
immaterial gain and proceeds of $5 million in the six months ended June 30, 2019. There were no sale-leaseback transactions in the three months ended June 30, 2019 or the three and six months ended June 30, 2018.

Store Rationalization Charge
During the six months ended June 30, 2019, the Company performed a review of its retail stores and determined it would close 46 underperforming retail pharmacy stores during the second quarter of 2019. As a result, management determined that there were indicators of impairment with respect to the impacted stores, including the operating lease right-of-use assets. Accordingly, an interim long lived asset impairment test was performed. The results of the impairment test indicated that the fair value of each store asset group was lower than the carrying value. The fair value was determined using a discounted cash flow method based on estimated sublease income. In the six months ended June 30, 2019, the Company recorded a store rationalization charge of $135 million, primarily related to these operating lease right-of-use asset impairment charges, which was recorded within operating expenses in the Retail/LTC Segment.